219 -4 (78) 2025 - Narzullaeva D.S. - CHRONIC HEART FAILURE AND FACTORS LEADING TO ITS DECOMPENSATION

CHRONIC HEART FAILURE AND FACTORS LEADING TO ITS DECOMPENSATION

Narzullaeva D.S. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This study aims to identify the factors triggering decompensation of chronic heart failure (CHF) and the clinical indicators associated with this condition. The research analyzed clinical symptoms, hemodynamic indicators, and causes of decompensation. The results showed that the main factors triggering CHF decompensation are non-compliance with medication, heart rhythm disturbances, and respiratory system infections. In addition, hypertensive crises and instability in blood pressure are also significant factors. The results of this study will assist in the development of individualized treatment strategies for patients.

Keywords: Chronic heart failure (CHF), Decompensation, heart rhythm disturbances, hypertensive crisis, ejection fraction, hemodynamic indicators.

First page

1212

Last page

1218

For citation:Narzullaeva D.S. - CHRONIC HEART FAILURE AND FACTORS LEADING TO ITS DECOMPENSATION//New Day in Medicine 4(78)2025 1212-1218 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Wilson Tang W.H., Marcy T.R., Ripley T.L. Aldosterone antagonists in the treatment of heart failure. Am. J. Health Syst. Pharm. 2006;63(1):49–58
  2. Место эплеренона в терапии сердечно-сосудистых заболеваний С.Н. Толпыгина ФГБУ «Государственный научно-исследовательский центр профилактической медицины», отдел профилактической фармакотерапии, г. Москва
  3. Pitt B., Reichek N., Wilenbrock R., et al.effects of eplerenone, enalapril, andeplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrofhy study // Circulation. 2003; 108 (15): 1831-1838.
  4. Zannad, F., et al. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine, 364(1), 11-21.
  5. Pitt, B., et al. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348(14), 1309-1321.
  6. Rossignol, P., et al. (2014). Aldosterone antagonists in heart failure: current role and future perspectives. European Heart Journal, 35(33), 2067-2075.
  7. Konstam, M. A., et al. (2009). The use of eplerenone in the treatment of heart failure. American Journal of Cardiology, 103(12), 1616-1622.
  8. McMurray, J. J. V., et al. (2007). Eplerenone in patients with systolic heart failure and mild symptoms. Journal of the American College of Cardiology, 49(11), 1511-1518.

    file

    download